Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Chromocell Therapeutics Corp ( (CHRO) ) just unveiled an update.
Channel Therapeutics Corporation, formerly Chromocell Therapeutics, has rebranded and reincorporated to emphasize its focus on non-opioid pain treatments using sodium channel modulation. The company is advancing its therapeutic programs, including eye pain and depot programs, with efficacy results anticipated soon. This strategic move is aimed at enhancing growth, valuation, and tax benefits.
Find detailed analytics on CHRO stock on TipRanks’ Stock Analysis page.
